Novo Nordisk reported a 65% increase in Q1 2026 operating profit, driven by a provision reversal related to the US 340B Drug Pricing Program and strong sales of its new Wegovy pill for obesity. Adjusted sales excluding the provision reversal fell 4% due to lower prices but were supported by GLP-1 volume growth. The Wegovy pill, launched in January 2026, quickly reached over 2 million prescriptions, marking the strongest GLP-1 launch in the US. Novo Nordisk raised its 2026 outlook, expecting adjusted sales and operating profit growth between -4% and -12% at constant exchange rates, reflecting confidence in GLP-1 product demand and ongoing pipeline progress.
Willow Tree Research initiates coverage of Novo Nordisk with a BUY rating and a $68 price target, citing the attractive valuation. The launch of oral Wegovy is expanding the obesity treatment market rather than just replacing injectable versions, sup...
Novo Nordisk's adjusted revenue fell 10.3% year-over-year, mainly due to weaker sales of Ozempic and Rybelsus, although profitability and cash flow have improved. The company’s drug pipeline in obesity and diabetes shows promise with candidates like ...
Novo Resources Corp's initial reverse circulation drilling at its Wyloo Polymetallic Project in Western Australia uncovered a significant hydrothermal alteration system with high-grade silver and antimony mineralisation from surface. This discovery i...
Eli Lilly announced plans to file for FDA approval of retatrutide, a new weight-loss drug, following phase 3 trials where participants lost an average of nearly 56 pounds over 80 weeks. The drug targets multiple hormones affecting appetite and metabo...
Novo Resources has filed a technical report confirming the mineral resource estimate for the Leven Star Reef gold project in Victoria, Australia, matching earlier estimates. Additionally, drilling at the Wyloo Polymetallic Project in Western Australi...
